Reduction in basic fibroblast growth factor mediated angiogenesis in vivo by linomide

Arnon Nagler*, Regina Feferman, Shmuel Shoshan

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

6 Scopus citations

Abstract

Linomide (N-phenylmethyl-1,2-dihydro-4-hydroxyl-1-methyl-2-oxoquinoline-3-carboxamide) is a novel immunomodulator with a potent anti-tumoral activity. This study was undertaken to test the effect of Linomide on basic fibroblast growth factor (bFGF) induced angiogenesis in vivo, which manifests itself in an increased number of blood vessels per unit of cell infiltrated area. Subcutaneously implanted polyvinyl alcohol sponges (PVS) in guinea pigs were used as a model system to quantitate angiogenesis in vivo. Oral treatment with Linomide was able to reduce significantly the bFGF induced blood vessel growth and proliferation within the implanted PVS, relative to untreated controls. In addition, Linomide significantly reduced the bFGF mediated augmentation of protein and collagen content in the implanted PVS, indicating an inhibition in the deposition of extracellular matrix (ECM). We conclude that the potent inhibition of bFGF induced angiogenesis by Linomide in vivo in addition to immunomodulatory effects may have potentially important clinical applications.

Original languageEnglish
Pages (from-to)61-68
Number of pages8
JournalConnective Tissue Research
Volume37
Issue number1-2
DOIs
StatePublished - 1998
Externally publishedYes

Fingerprint

Dive into the research topics of 'Reduction in basic fibroblast growth factor mediated angiogenesis in vivo by linomide'. Together they form a unique fingerprint.

Cite this